These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 23663200)
1. The hallmarks of Parkinson's disease. Antony PM; Diederich NJ; Krüger R; Balling R FEBS J; 2013 Dec; 280(23):5981-93. PubMed ID: 23663200 [TBL] [Abstract][Full Text] [Related]
2. Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies. Bisaglia M; Greggio E; Beltramini M; Bubacco L FASEB J; 2013 Jun; 27(6):2101-10. PubMed ID: 23463698 [TBL] [Abstract][Full Text] [Related]
3. Caenohabditis elegans in Parkinson's disease drug discovery: addressing an unmet medical need. Nass R; Merchant KM; Ryan T Mol Interv; 2008 Dec; 8(6):284-93. PubMed ID: 19144901 [TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein and Parkinson's disease: a proteomic view. Fasano M; Lopiano L Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054 [TBL] [Abstract][Full Text] [Related]
5. Genetics and iron in the systems biology of Parkinson's disease and some related disorders. Funke C; Schneider SA; Berg D; Kell DB Neurochem Int; 2013 Apr; 62(5):637-52. PubMed ID: 23220386 [TBL] [Abstract][Full Text] [Related]
6. Advances in the genetics of Parkinson's disease. Rosner S; Giladi N; Orr-Urtreger A Acta Pharmacol Sin; 2008 Jan; 29(1):21-34. PubMed ID: 18158863 [TBL] [Abstract][Full Text] [Related]
10. Comparing Alzheimer's and Parkinson's diseases networks using graph communities structure. Calderone A; Formenti M; Aprea F; Papa M; Alberghina L; Colangelo AM; Bertolazzi P BMC Syst Biol; 2016 Mar; 10():25. PubMed ID: 26935435 [TBL] [Abstract][Full Text] [Related]
11. C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease. Harrington AJ; Hamamichi S; Caldwell GA; Caldwell KA Dev Dyn; 2010 May; 239(5):1282-95. PubMed ID: 20108318 [TBL] [Abstract][Full Text] [Related]
12. The importance of Wnt signalling for neurodegeneration in Parkinson's disease. Berwick DC; Harvey K Biochem Soc Trans; 2012 Oct; 40(5):1123-8. PubMed ID: 22988876 [TBL] [Abstract][Full Text] [Related]
13. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. During MJ; Kaplitt MG; Stern MB; Eidelberg D Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246 [TBL] [Abstract][Full Text] [Related]
14. Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD. Mandel SA; Fishman T; Youdim MB Parkinsonism Relat Disord; 2007; 13 Suppl 3():S242-7. PubMed ID: 18267243 [TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068 [TBL] [Abstract][Full Text] [Related]
16. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease. Ulusoy A; Decressac M; Kirik D; Björklund A Prog Brain Res; 2010; 184():89-111. PubMed ID: 20887871 [TBL] [Abstract][Full Text] [Related]